The overexpression constructs of Oct4 (pcDNA 3.3 OCT4, plasmid no. 26816), Sox2 (pSin-EF2-Sox2-Pur, plasmid no. 16577), HDAC1 (HDAC1 Flag, plasmid no. 13820), and the shRNAs against Oct4 (LL-HOCT4i, plasmid no. 12198), and Sox2 (pLKO.1 Sox2 3H b, plasmid no. 26352) were purchased from Addgene. The ABCG2 siRNA (NM_004827), HDAC1 siRNA (NM_004964), and HDAC2 siRNA (NM_001527) were purchased from Sigma-Aldrich. The SMAR1 overexpression plasmid (SMAR1 cDNA) and SMAR1 shRNA were gifts from S. Chattoadhyay (10, 14). The SMAR1 overexpression plasmid produces a GFP-tagged SMAR1 protein that gives a separate band of external SMAR1-GFP when visualized in Western blot (10).
The plasmids and control vectors were introduced into cells and spheres using Lipofectamine-2000 (Invitrogen) according to the protocol provided by the manufacturer. Stably expressing clones were isolated by limiting dilution and selection with puromycin dihydrochloride (1 μg/ml; Sigma-Aldrich) or G418 Sulfate (1 mg/ml; Sigma-Aldrich), and the resistant cells were cloned and screened by Western blotting with specific antibodies. The siRNA were transfected using Lipofectamine-2000, and cells were harvested after 34 to 36 hours after which the knockdown efficiency was determined using Western blot.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.